Clinical experience with single-agent gemcitabine chemotherapy in patients with non-small-cell lung cancer in whom previous chemotherapy has failed

Journal of the Chinese Medical Association

Volumn 68, Issue 4, 2005, Pages 163-166

  Chen, Yuh Min ^a   Tsai, Chun Ming ^a   Perng, Reury Perng ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Gemcitabine; Non small cell lung cancer; Salvage therapy

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 17244369672     PISSN: 17264901     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1726-4901(09)70242-4     Document Type: Article

References (18)

1. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18:2354-62.
2. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
3. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-53.
4. Perng RP, Chen YM, Liu JM, Tsai CM, Lin WC, Yang KY, Whang-Peng J. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 1997;15: 2097-102.
5. Evans WK, Kocha W, Gagliardi A, Eady A, Newman TE. The use of gemcitabine in non-small-cell lung cancer. Cancer Prev Control 1999;3:84-94.
6. Crino L, Mosconi AM, Scagliotti G, Selvaggi G, Novello S, Rinaldi M, Delia Giulia M, et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1999;17:2081-5.
7. Van Kooten M, Traine G, Cinat G, Cazap E, Comba AZ, Vicente H, Sena S, et al. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial. Br J Cancer 1999;81: 846-9.
8. Sculier JP, Lafitte JJ, Berghamans T, Thiriaux J, Lecomte J, Efremidis A, Ninane V, et al. A phase II trial testing gemcitabine as second-line chemotherapy for non-small-cell lung cancer. Lung Cancer 2000;29:67-73.
9. van Putten JW, Baas P, Codrington H, Kwa HB, Muller M, Aaronson N, Groen HJ. Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer. Lung Cancer 2001;33:289-98.
10. Gridelli C, Perrone F, Gallo C, Rossi A, Barletta E, Barzelloni ML, Creazzola S, et al. Single-agent gemcitabine as second-line treatment in patients with advanced non-small-cell lung cancer (NSCLC): a phase II trial. Anticancer Res 1999;19: 4535-8.
11. Oken MM, Creech PH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
12. Belani CP. Single agents in the second-line treatment of non-small cell lung cancer. Semin Oncol 1998;25(Suppl 8):10-4.
13. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
14. Niho S, Kubota K, Goto K, Ohmatsu H, Matsumoto T, Kakinuma R, Nishiwaki Y, et al. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial. Cancer Chemother Pharmacol 2003; 52:19-24.
15. Chen YM, Perng RP, Lin WC, Wu HW, Tsai CM, Whang-Peng J. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol 2002;25:509-12.
16. Chen YM, Perng RP, Lee CS, Lin WC, Tsai CM, Whang-Peng J. Phase II study of gemcitabine and vinorelbine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol 2003;26:567-70.
17. Pectasides D, Kalofonos HP, Samantas E, Nicolaides C, Papacostas P, Onyenadum A, Visvikis A, et al. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic Co-operative Oncology Group. Anticancer Res 2001; 21:3005-10.
18. Androulakis N, Kouroussis C, Kakolyris S, Tzannes S, Papadakis E, Papadimitriou C, Geroyianni A, et al. Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study. Ann Oncol 1998;9: 1127-30.